Zacks Research Issues Optimistic Estimate for CPRX Earnings

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) – Zacks Research boosted their Q1 2026 EPS estimates for Catalyst Pharmaceuticals in a report released on Wednesday, March 18th. Zacks Research analyst Team now anticipates that the biopharmaceutical company will post earnings per share of $0.57 for the quarter, up from their prior forecast of $0.53. Zacks Research currently has a “Strong-Buy” rating on the stock. The consensus estimate for Catalyst Pharmaceuticals’ current full-year earnings is $1.90 per share. Zacks Research also issued estimates for Catalyst Pharmaceuticals’ Q2 2026 earnings at $0.58 EPS, Q4 2026 earnings at $0.67 EPS, FY2026 earnings at $2.48 EPS, Q1 2027 earnings at $0.71 EPS, Q2 2027 earnings at $0.69 EPS, Q4 2027 earnings at $0.67 EPS and FY2027 earnings at $2.76 EPS.

A number of other research firms also recently weighed in on CPRX. Citigroup boosted their target price on Catalyst Pharmaceuticals from $33.00 to $35.00 and gave the stock a “buy” rating in a research report on Tuesday, March 3rd. Weiss Ratings reiterated a “buy (b-)” rating on shares of Catalyst Pharmaceuticals in a research report on Monday, December 29th. Two equities research analysts have rated the stock with a Strong Buy rating and three have assigned a Buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $34.00.

Catalyst Pharmaceuticals Stock Performance

Shares of CPRX opened at $22.79 on Monday. The business’s fifty day moving average price is $23.95 and its two-hundred day moving average price is $22.59. The firm has a market capitalization of $2.78 billion, a price-to-earnings ratio of 13.49, a PEG ratio of 0.66 and a beta of 0.75. Catalyst Pharmaceuticals has a 52 week low of $19.05 and a 52 week high of $26.58.

Institutional Investors Weigh In On Catalyst Pharmaceuticals

A number of hedge funds have recently modified their holdings of CPRX. Rothschild Investment LLC lifted its holdings in shares of Catalyst Pharmaceuticals by 1,085.7% during the 3rd quarter. Rothschild Investment LLC now owns 1,660 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 1,520 shares in the last quarter. Advisory Services Network LLC bought a new stake in Catalyst Pharmaceuticals during the 3rd quarter worth approximately $39,000. Quarry LP acquired a new stake in Catalyst Pharmaceuticals during the 3rd quarter worth approximately $40,000. Clearstead Advisors LLC raised its holdings in Catalyst Pharmaceuticals by 192.9% during the 4th quarter. Clearstead Advisors LLC now owns 1,772 shares of the biopharmaceutical company’s stock worth $41,000 after buying an additional 1,167 shares during the period. Finally, Smartleaf Asset Management LLC lifted its stake in Catalyst Pharmaceuticals by 55.6% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,764 shares of the biopharmaceutical company’s stock valued at $41,000 after buying an additional 630 shares in the last quarter. Institutional investors and hedge funds own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).